The new €350m ($386m) biotechnology research center will help power Boehringer Ingelheim’s development of biopharmaceuticals, which account for around 50% of the company’s research pipeline.
Boehringer Ingelheim today inaugurated its state-of-the-art Biologicals Development Center (BDC) in Biberach an der Riß, Germany. The new high-tech facility underlines the company’s strong commitment to Germany and Europe as location for research and development (R&D) for the care of patients around the world. With .
VANCOUVER, BC / ACCESSWIRE / April 24, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to announce that it has signed and received payment for a development
BioNxt Secures Contract to Develop and Manufacture ODF Product for International Pharmaceutical Company parisguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from parisguardian.com Daily Mail and Mail on Sunday newspapers.